Drug intelligence / Profile preview

rAAV-CYP2J2

Development stage: Preclinical
Lead developer: Huazhong University of Science and Technology
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

rAAV-CYP2J2 is an experimental gene therapy consisting of a recombinant adeno-associated virus (rAAV) vector, typically serotype 2, designed to deliver the human cytochrome P450 epoxygenase 2J2 (CYP2J2) gene. CYP2J2 is a key enzyme that metabolizes arachidonic acid into four regioisomeric epoxyeicosatrienoic acids (EETs), which are bioactive lipids with potent vasodilatory, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. In preclinical models of chronic renal failure and hypertension, delivery of rAAV-CYP2J2 has been shown to increase EET generation, attenuate blood pressure elevation, and protect against renal damage by inhibiting TGF-β1/SMAD signaling and reducing glomerular sclerosis. The therapy is primarily investigated for its potential in treating chronic kidney disease and associated cardiovascular disorders.

Other names: recombinant adeno-associated virus-mediated CYP2J2AAV-mediated CYP2J2 gene delivery

Targets

CYP2J2 (Cytochrome P450 family 2 subfamily J member 2)

Beyond the preview

Go deeper on rAAV-CYP2J2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rAAV-CYP2J2.

Explore the full profile